Mark Zalupski is Clinical Professor Emeritus at University of Michigan. OpenAlex indexes 380 publications with 11,287 citations (h-index 50); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 21 Oct 2026
Overview
Updated 21 Oct 2026
Mark Michael Zalupski, MD, is Clinical Professor Emeritus at University of Michigan. The public record shows 380 publications with 11,287 citations (h-index 50), centered on Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatitis Pathology and Treatment. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 1 companies, 4 NIH-funded awards (1997–2022).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Pancreatic and Hepatic Oncology Research
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 126.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Sponsor: University of Michigan Rogel Cancer Center
- A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Sponsor: University of Michigan Rogel Cancer Center
- A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Sponsor: University of Michigan Rogel Cancer Center
Industry payments
Updated 21 Oct 2026
1 company reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.6%Proton pump inhibitor18.5%Omeprazole100%Part D≥21 patientsSerotonin-3 Receptor Antagonist16.8%Ondansetron Hcl75%Ondansetron Odt25%Part D<11 patients+ 3 more classes in this area
Nervous system
26.2%Phenothiazine14.3%Prochlorperazine Maleate100%Part D≥27 patientsAtypical Antipsychotic8%Olanzapine100%Part D≥15 patients+ 1 more class in this area
Blood & clotting
4.2%Factor Xa inhibitor4.2%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 21 Oct 2026
4 NIH research awards on record, funded 1997–2022 per NIH RePORTER. The latest:
Congress activity
Updated 21 Oct 2026
82 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Perioperative versus adjuvant therapy in resectable pancreas cancer.
ASCO Annual Meeting
ASCO2025Co-author - Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors.
ASCO Annual Meeting
ASCO2025Co-author - Abstract C013: Analysis of tumor immune microenvironment and clinical outcomes in undifferentiated pancreatic carcinomas with and without osteoclast-like giant cells
AACR (meeting unresolved)
AACR2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.
Clinical cancer research
Clinical Trial2026 - Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells.
JNCI cancer spectrum
Article2025 - A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Clinical cancer research
Clinical Trial2024 - Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Integrative clinical genomics of metastatic cancerArticle861 citations2017
- 02Identification of Targetable FGFR Gene Fusions in Diverse CancersArticle744 citations2013
- 03
- 04
- 05
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mark-zalupski-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH